Tempus AI reported an impressive revenue increase of 89.6%, reaching $314.6 million. The Genomics segment led the charge with a 115% rise to $241.8 million, while Data and Services revenue grew by ...

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

August 8, 2025Tempus AI, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.23. Operator: Thank you for standing by, and welcome to Tempus AI Second Quarter 2025 Financial ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Magnus Tempus 360—a visionary initiative dedicated to forging new curatorial and collaborative pathways across the Mediterranean.

A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

In trading on the Nasdaq as of 1:17 p.m. Central, Tempus' stock price was $60.65, up 3.2% from the previous day's close.

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient ...